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Two patients with linear scleroderma (en coup de 
sabre) developed systemic lupus erythematosus (SLE). 
This association has been well documented in only one 
previous case. The presence of high titer antibodies to 
ribonucleoprotein (RNP) initially led to the diagnosis of 
the mixed connective tissue disease. Development of 
more serious clinical involvement and antibodies to Sm 
(case 1) or native deoxyribonucleic acid (nDNA) (case 2) 
helped establish a diagnosis of SLE. Use of these studies 
in the differential diagnosis of systemic rheumatic dis-
eases is discussed briefly. The presence of anti-RNP 
antibodies in patients with localized scleroderma may 
herald a more serious rheumatic disease. 
We wish to report 2 unusual patients with coexistent linear 
scleroderma and SLE who presented with high titers of anti-
body to the RNP component of extractable nuclear antigen 
(ENA) . ENA is a crude saline extract of thymus comprised of 
a number of antigens including the ribonuclease (RNase) and 
trypsin-sensitive nuclear antigen known as RNP and the 
RNase-resistant, trypsin-resistant Sm antigen [1-3). These an-
tigens can be detected by hemagglutination reactions or gel 
diffusion [1,3,4). A syndrome in which high titer serum antibody 
to RNP and clinical features of more than one connective tissue 
disease, including systemic sclerosis, SLE, rheumatoid arthritis, 
and polymyositis are present is known as the mixed connective 
tissue disease (MCTD) [5). Patients with this syndrome appear 
to exhibit a more benign course and may have a reduced 
incidence of serious renal involvement [1,3,5-10). Since the 
ARA preliminary criteria for SLE were satisfied in our 2 pa-
tients, we believe they represent examples of 2 concomitant 
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Abbreviations: 
ANA: antinuclear antibodies 
ARA: American Rheumatism Association 
ENA: extractable nuclear antigen 
IF: immunofluorescence 
MCTD: mixed connective tissue disease 
mRF: monoclonal rheumatoid factor 
nDNA: native deoxyribonucleic acid 
RNase: ribonuclease 
RNP: ribonucleoprotein 
SLE: systemic _lupus erythematosus 
diseases, linear scleroderma and SLE, despite the fact they also 
fit the clinical spectrum of MCTD [11). 
The use of the term "MCTD" may delay recognition of a 
more serious disease in patients with high titers of antibody to 
nuclear RNP. It is essential to observe these patients carefully 
and to test them periodically for appearance of other antinu-
clear antibodies that may indicate development of a more 
serious disease process. 
Investigational Studies 
Antinuclear antibodies (ANA) were detected by standard 
immunofluorescence methods using mouse liver sections [12). 
Antibodies to nDNA were detected by precipitation with am-
monium sulfate (Farr technique) [13). Antibodies to Sm and 
RNP were measured by double immunodiffusion (Ouchterlony) 
as previously described [4). Briefly, antigen was extracted from 
young rabbit thymus (Pel Freeze Biologicals, Rogers, Arkan-
sas), as reported by Kurata and Tan [14]. RNP activity was 
destroyed by prior incubation of antigens with pancreatic 
RNase (Type III-A, Sigma Chemical Co., St. Louis, Missouri) . 
Sm and RNP were identified by the presence of identity arcs 
with reference serums to these antigens, and the absence of a 
reaction with RNase-treated antigen confumed the presence of 
RNP. 
Skin biopsy specimens were immediately frozen in liquid 
nitrogen and stored at -70°C until sectioned. Direct immuno-
fluorescence (IF) staining was performed by methods previously 
described, using monospecific fluorescein-conjugated antisera 
to IgG, IgM, IgA, C3, Clq and fibrin [15). 
Sera for immune complex studies were separated from freshly 
drawn blood and kept frozen at -70°C until tested. Each sample 
was assayed by 2 different methods for the detection of circu-
lating immune complexes: (1) The monoclonal rheumatoid 
factor (mRF) inhibition assay performed by the method of 
.Luthra et al [16], and (2) the Clq binding assay performed by 
the method of Nydegger et al [17], with modifications described 
by Tappeiner et al [18). 
Case 1 
A 23-yr-old Mexican-American woman was referred to the 
Dermatology Clinic in July 1977 with a rash on her face and 
upper arms which had recurred every summer for 6 yr. She also 
complained of the recent onset of arthralgias and fatigue, but 
denied fever, weight loss, dysphagia, or Raynaud's phenome-
non. H er only medication was a topical steroid cream. She was 
fust seen by a dermatologist for hair loss 3 years prior to this 
visit. At that time, a linear scarring lesion of the scalp was 
noted which showed changes consistent with morphea histolog-
ically. One year later a facial lesion was biopsied which revealed 
changes characteristic of lupus erythematosus. At that time, an 
ANA was positive at 1:80, and a diagnosis of discoid lupus 
erythematosus was made. 
When evaluated, abnormalities were limited to the skin. 
Discoid, slightly erythematous papules and hyperpigmented 
macules were noted on her cheeks and upper arms. A 10 cm 
linear scalp lesion with alopecia and depressed sclerosis, but 
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without erythematous borders, was present. A total leukocyte 
count was 3800/mm3 with a normal differential, and an eryth-
rocyte sedimentation rate (Westergren) was 56 mm/hr. The 
following tests were normal or negative: hemoglobin, VDRL, 
serum immunoglobulins, cryoglobulins, BUN, creatinine, 
SGOT, bilirubin, lactic acid dehydrogenase, alkaline phospha-
tase, uric acid, glucose, CPK, calcium, phosphorus, serum elec-
trolytes and creatinine clearance. Chest X-ray, EKG and bar-
ium swallow were normal. A urinalysis revealed 60-100 WBCs 
and bacteria, but no protein or erythrocytes; the culture grew 
>100,000 colonies of Escherichia coli. Serologic tests were as 
follows: LE cell preparation, positive; ANA, positive at 1:480 in 
a homogeneous pattern; rheumatoid factor, positive at 1:160; 
CH50, 68 mg/dl (normal 89-132 mg/dl); C4 , 9 mg/dl (normal 12-
72 mg/dl); anti-nDNA antibodies, 15.6% (normal <11%); and 
ENA, positive for both anti-RNP antibody at a serum dilution 
of 1:4 and anti-Sm antibody, neat (Fig 1). 
Histologically, the scalp lesion demonstrated diffuse fibrosis 
and hyalinization of dermal collagen with entrapment of the 
sweat glands, a pattern consistent with scleroderma (Fig 2). By 
direct IF, biopsies of normal exposed forearm skin and normal 
nonexposed buttock skin showed dermal-epidermal deposition 
of IgG, IgM, C3, Clq and fibrin in a granular pattern. Deposition 
of IgM, C3 and fibrin in superficial blood vessels was noted. 
Epidermal nuclear staining was not observed. Low levels of 
irrunune complexes were detected by both Clq binding and 
rnRF inhibition assays. 
A presumptive diagnosis of SLE and concurrent linear scle-
roderma was made, since the patient fulfilled the preliminary 
ARA criteria for SLE (discoid LE skin lesions, alopecia, leuko-
penia, and positive LE cells/ANA) [11]. She was treated with 
hydroxychloroquin (200 mg/day) and sunscreens. Her urinary 
tract infection was treated with an antibiotic. 
The patient's rash gradually cleared, the arthralgias dimin-
ished, but the scalp lesion remained unchanged. The rheuma-
toid factor, CHr.o, and CBC returned to normal, and t.he ESR 
decreased to 28 mm/hr. Anti-nDNA antibody titers remained 
FIG 1. Case 1. Double diffusion of serum and control known to 
contain antibodies to both 8m (closed arrow) and RNP (open arrow) . 
Note lines of identity between this case and control serum and disap-
pearance of the anti-RNP-RNP line after treatment of antigen with 
RNase. 
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FIG 2. Casel. Biopsy specimen of scalp lesion showing epidermal 
atrophy and diffuse fibrosis of dermis (hematoxylin-eosin, reduced from 
x50). 
normal. In January 1978, the ANA was 1:1000 with a speckled 
pattern. In July 1978, repeat direct IF of normal exposed 
forearm skin showed' minimal IgM deposition at the dermal-
epidermal junction. 
Case 2 
In July 1975, a 9-yr-old native American girl was admitted to 
Milwaukee Children's Hospital with a 2-day history of fever, 
fatigue, and arthritis of the hands, knees and ankles. Her past 
medical history was unremarkable except for a lesion of the 
forehead which had been present for approximately 1 yr. A 
biopsy ofthis lesion demonstrated thickening of dermal collagen 
with atrophy of rete pegs; these changes are characteristic of 
scleroderma. 
On physical examination, a depressed, depigmented sclerotic 
lesion extended along the midline from her nose to the hairline. 
Malar erythema was apparent. Fusiform swelling of the fingers 
and warmth and swelling of the knees and feet were present. 
Laboratory studies showed a normal CBC, BUN, creatinine, 
alkaline phosphatase, bilirubin and urinalysis. Other studies 
were as follows: LDH, 1050 IV (normal 40-110 IV); SGOT, 156 
IV (normal 5-30 IU); aldolase, 1.532 IV (normal 0.285-0612 
IU); and ESR, 65 mm/hr (Westergren). Serum protein electro-
phoresis revealed a polyclonal gammopathy. Additional studies 
included a positive LE cell preparation, positive ANA with a 
speckled pattern, a negative rheumatoid factor, and negative 
anti-nDNA antibodies (performed elsewhere) . Anti-RNP anti-
bodies were found at a titer of 1:10,000 (hemagglutination 
method, also performed elsewhere). Chest X-ray, esophagram 
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and IVP were normal. A diagnosis of MCTD was made, and 
treatment with aspirin was initiated. 
The patient was well until November 1975 when she was 
rehospitalized because of fatigue and severe diarrhea. In addi-
tion to the malar erythema and the en coup de sabre lesion, a 
violacious hue was noted around her eyes. Purpuric lesions 
were present on both legs and around her waist. In addition to 
the previous serological abnormalities, a depressed C3 of 64 
mg/dl (normal 116-164 mg/dl) was found . The urinalysis 
showed 1+ protein, 3+ hemoglobin and numerous red blood 
cells. Skin biopsy of an erythematous macule on her leg showed 
no evidence of leukocytoclastic vasculitis. A kidney biopsy was 
attempted but was unsuccessful. A muscle biopsy showed 
changes consistent with polymyositis. The patient was treated 
with 10 mg prednisone daily. 
In July 1976, a successful renal biopsy was performed and 
showed membranoproliferative glomerulonephritis and IF 
staining with anti-IgG, IgA, IgM and C3. Despite treatment 
with high doses of prednisone, her renal function deteriorated. 
The renal biopsy was repeated in August 1977 and showed 
interstitial nephritis as well as membranoproliferative glomer-
ulonephritis. Cyclophosphamide was started but discontinued 
after 11 days due to leukopenia. 
In July 1978, she returned to the hospital with nausea, 
vomiting, diarrhea and oliguria. Her blood pressure was 170/ 
1l0, BUN 196 mg/dl and serum creatinine 16 mg/d!. She was 
transferred to the Milwaukee County Medical Complex for 
hemodialysis. In addition to renal failure, she had pleural and 
pericardial effusions and a Coombs-positive hemolytic anemia. 
Direct IF of normal skin showed blood vessel deposition of IgM 
and epidermal nuclear speckling with IgG. No dermal-epider-
mal fluorescence was apparent (Fig 3). Anti-RNP antibodies 
were detected at a serum dilution of 1:512, but no anti-Sm 
antibody was apparent (Fig 4). The ANA was positive at 1:5120, 
speckled, and anti-nDNA antibody was elevated with 82% 
binding. Serum, obtained in 1977 and stored at -70°C, waS 
tested for immune complexes by the Clq and mRF radioassays. 
High levels of circulating immune complexes were detected by 
the Clq binding assay, while the mRF radio assay was normal. 
Similar values were obtained from serum prior to dialysis in 
1978, but postdialysis levels were normal. 
FIG 3. Case 2. Direct immunofluorescence of normal skin showing 
epidermal nuclear speckling with anti-IgG (reduced from x250). 
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FIG 4. Case 2. Double diffusion of serum versus untreated ENA. 
Note the presence of both anti-8m and anti-RNP antibodies in control 
(C) weU. Anti-RNP is present in titers of 1:16 in this illustration. 
DISCUSSION 
The 2 patients described here had coexistent linear sclero-
derma and SLE. In both cases, the linear scleroderma developed 
several years before the onset of SLE. The association of these 
2 diseases has been well documented in only one previously 
reported case [19,20] although it has been suggested by several 
authors (Table) [21,22]. 
Overlap syndromes in which features of several connective 
tissue diseases are present are well recognized [23-27]. As many 
as 12% of patients with progressive systemic sclerosis (sclero-
derma) also have clinical features of SLE [20]. However, this 
does not appear to be true for patients with the more benign or 
localized forms of scleroderma, linear scleroderma and mor-
phea, since our review of the literature has disclosed only 1 
definite and 4 possible cases (Table) . 
Another overlap syndrome recently described by Sharp and 
co-workers is the MCTD [5]. Clinically, the MCTD syndrome 
is characterized by features of scleroderma (Raynaud's phenom-
enon, dysphagia, hand and finger edema, and sclerodactaly), 
SLE (skin changes and photosensitivity, and neurologic, renal 
and hematologic abnormalities), polymyositis and rheumatoid 
arthritis [5,7,9,10]. It has been suggested that the MCTD is a 
more benign disease than SLE, since renal involvement is less 
common and less severe when present [1,3,5-10]. Patients with 
MCTD have high titers of circulating antibody to a saline 
extractable antigen from crude thymus preparations which are 
sensitive to RNase digestion [1-3]. This antigen, RNP, is not 
specific for the MCTD as it is found in 15-25% of patients with 
SLE, 9-22% of patients with scleroderma, and in a number of 
other rheumatic diseases [28-30]. While antibody to RNP has 
been detected in at least 1 other patient with localized sclero-
derma [3], the true frequency of this antibody in linear sclero-
derma or morphea is not known. 
The presence of other antinuclear antibodies may be useful 
in differentiating these systemic connective tissue diseases. 
Antibody to Sm, an acidic nuclear antigen, is thought to be 
highly specific for SLE [30]. This antigen is also obtained by 
. saline extraction of thymus, but antibodies to Sm can be differ-
entiated from RNP by their resistance to RNase and the 
presence of identity arcs in agarose gels when standard refer-
ence sera are used [4]. Antibodies to nDNA are virtually 
pathognomonic of SLE, while anti-single stranded DNA anti-
bodies may be found in other connective tissue diseases [30]. A 
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A review of cases with coexistent linear scleroderma or morphea and SLE 
Duration Laboratory findings 
Reference Cutaneous un til diag· Clinical features of SLE diagnosis nosis of Direct LE Anti- Anti- Anti-
SLE (yr) IF Cells ANA nONA RNP Sm 
Tufanelli et al 
} 
Facial erythema, photosensitivity 
D ubois et al LS 12 Arthritis Leukopenia (Case 12)" Renal disease (proteinuria) 0 + 0 0 0 
D ubois et al 
~ Discoid LE, photosensitivity Case 13 M 11 Malar rash 0 + 0 0 0 Arthritis 
Case 14" M ? Arthralgia 0 + 0 0 0 
Scarola, Shulman LS 15 Not described 0 0 0 0 0 0 
U mbert, Winkelman LS 3 Discoid LE, leukopenia + ± 0 ± 0 0 
M ackel et al' 
Case 1 LS 3 Arthirt is, leukopenia + + + + + Discoid LE, alopecia (±) 
Arthritis, polyserositis 
Case 2 LS Malar rash, hemolytic anemia + + + + 
Glomerulonephrit is 
" This was the same patient reported initially by Tuffanelli (personal communication) . 
" This patient does not fulfill ARA preliminary criteria for SLE. 
C Present report: LS = linear scleroderma; M = morphea; + = present; - = absent; and 0 = not reported. 
number of other antinuclear antibodies have been identified 
a nd th e ir clinical associations defined; this subject has recently 
b een r eviewed [32,33]. 
It is of interest that bot h pa tients reported h ere had anti-
b o dies to RNP a nd initially were thought to h ave the MCTD 
s yndrome. Some of the clinical a nd laboratory findings in our 
patients, including arthritis, presence of positive lupus band 
test, depressed total hemolytic complement, leukopenia and 
his topathologic features of SLE or scleroderma, have been seen 
in patients wit h MCTD [5-7,34,35]' However, the presence of 
a n ti-S m an tibodies in case 1 and a nti-nDNA a ntibodies in case 
2 are indicative of SLE. 
Using t h e t erm "MCTD" may be helpful to the clinicia n 
when caring for patients who exhibit high levels of anti-RNP 
alon e and a spectrum of clinical features which are not typical 
for any s ingle connective tissue disease, since t hese patients 
a ppear to h ave a be t ter prognosis than those with SLE [1,3,5-
10]. But , as case 2 demonstra tes, it is important to observe 
t h ese pa tients carefully for the development of clinical or se-
rologic signs which would es tablish a more specific diagnosis. 
F o r example, when first examined, case 2 did not fulfill ARA 
criteria for the diagnosis of SLE [ll], a nd a diagnosis of MCTD 
appeared to be more appropriate. La ter , however, despite initial 
improvement wit h systemic s teroids, she developed severe clin-
i c al and serological (anti-nDNA a nt ibody) manifesta tions of 
SLE. 
Another feature which has been noted in SLE and MCTD is 
e pidermal nuclear speckling on direct IF of skin biopsy speci-
mens [36,37] in t h e presence of high titer antibody to ENA. In 
case 2, epidermal nuclear st a ining was present, thus supporting 
t h ese previous r eports. However , this case emphasizes the fact 
t h at epidermal nuclear sta ining should not be interpreted as a 
d iagn ostic ma rker for a more benign connective tissue disease 
process, but only for the presence of high titer a ntibody to 
R NP. The onset of glomerulonephritis in case 2 reemphasizes 
t h e well-esta blished prognostic importance of a ntibodies to 
nDNA [6,8,37,38]. 
The 2 pa tients presented h ere indicate that linear sclero-
d e rma in children may , in som e cases, precede the development 
of SLE. It is possible tha t the presence of antibody to nuclear 
RNP in such patients may indicate their potential to develop 
SLE or systemic involvement. To determine the significance of 
t h ese findings, it is important that the study of patients with 
linear scle roderm a include a t horough and periodic immunolog-
ical evluation. 
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